DI-UMONS : Dépôt institutionnel de l’université de Mons

Recherche transversale
(titres de publication, de périodique et noms de colloque inclus)
2014-09-03 - Colloque/Présentation - poster - Anglais - 1 page(s)

Lenaerts Charline , Bond Liz, Tuytten Robin, Blankert Bertrand , "Identification of marinobufagenin in plasma as a promising LC-MS assay for preeclampsia risk assessment" in MSACL, Salzburg, Autriche, 2014

  • Codes CREF : Anamnèse - diagnostic [biologie clinique] (DI3316), Chimie analytique (DI1314), Médecine clinique [chimie clinique] (DI3340), Pharmacognosie (DI3410), Gynécologie (DI3345), Sciences pharmaceutiques (DI3400), Chimie pharmaceutique (DI3413)
  • Unités de recherche UMONS : Analyse pharmaceutique (M130)
  • Instituts UMONS : Institut des Sciences et Technologies de la Santé (Santé)
  • Centres UMONS : Centre Interdisciplinaire de Spectrométrie de Masse (CISMA)
Texte intégral :

Abstract(s) :

(Anglais) Marinobufagenin (MBG) is a bufadienolide compound belonging to the cardiac glycoside class and is present in humans as well as in some plants and other animals. The major source for this compound is located in the parotid and skin gland secretions of some toad species, notably Bufo Marinus species. Endogenous mammalian MBG acts principally as a vasoconstrictive and cardiotonic compound that inhibits the α1 isoform of Na+,K+-ATPase, resulting in hypertension and natriuresis. The enhanced production of MBG has been described in mammals presenting volume expansion-mediated hypertensive states, notably in preeclamptic patients [1-3]. The elevation of endogenous MBG appears prior the development of the main symptoms of preeclampsia (PE), leading us to consider MBG as a potential biomarker for PE. Nowadays, a sensitive and accurate analytical method has become indispensable to assess MBG in as lower level as possible in plasma. A critical threshold value might be established by clinicians in the future, in order to predict the risk for preeclampsia in pregnant women. A MBG standard compound is currently not commercially available. It forced us to develop an effective extraction and purification method of MBG from freshly collected or crystallized toad Bufo Marinus venom. The identity of the compound has been confirmed by different spectral techniques. Currently, only marinobufagenin-like material has been found in humans using two published quantification methods based each on immunoassays. These techniques suffer from a lack of specificity due to cross-reactivity and tend to exhibit high variability at low concentrations [4]. This condition has led us to authenticate the presence of MBG in humans using a more specific and accessible technique. The research work currently presented deals with the optimization of a LC-MS based assay in order to identify and quantify MBG in human plasma. A pre-extraction procedure is needed to concentrate and clean the sample prior to its analysis. The identification of MBG in non-pregnant healthy volunteers as well as in early pregnancy will be demonstrated, giving the clinicians a promising opportunity for early preeclampsia risk assessment in pregnant women. References 1. Lopatin, D.A., et al., Circulating bufodienolide and cardenolide sodium pump inhibitors in preeclampsia. Journal of Hypertension, 1999. 17(8): p. 1179-1187. 2. Agunanne, E., et al., Marinobufagenin Levels in Preeclamptic Patients: A Preliminary Report. American Journal of Perinatology, 2011. 28(7): p. 509-514. 3. Vu, H.V., et al., Involvement of Marinobufagenin in a Rat Model of Human Preeclampsia. American Journal of Nephrology, 2005. 25(5): p. 520-528. 4. Jarvis, Ultra-sensitive analysis of aldosterone in serum using the AB SCIEX Triple QuadTM 6500 LC/MS/MS system, AB SCIEX, 5730212-01